A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Recruiting · Phase 2, Phase 3 · NCT07005102
Conditions: Non-Squamous Non-Small Cell Lung Cancer, c-MET
At a glance
- Research payments reported, 2025
- $110,715
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 854
About the trial
- Sponsor
- AbbVie
- Tested
- Standard of Care (drug), Telisotuzumab Adizutecan (drug), Osimertinib (Osi) (drug), Cisplatin (drug), Carboplatin (drug), Pemetrexed (drug)
- Dates
- Started 2025-08-03; completion 2036-11
- Results posted
- Not yet
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum/pemetrexed chemotherapy). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into…
From ClinicalTrials.gov, last updated 2026-10-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $110,715 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Azam Farooqui, M.D. Hematology & Oncology · Chandler, AZ
- Jorge J. Nieva, M.D. Hematology & Oncology · Los Angeles, CA
- Kartik Anand, MD Hematology & Oncology · Fort Dodge, IA
- Kailash Mosalpuria, M.D., MPH Hematology & Oncology · Lincoln, NE
- Katharine E. Thomas, M.D. Medical Oncology · Reno, NV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Southern California $32,525
- Renown Regional Medical Center, NV $26,884
- Nebraska Hematology Oncology PC $26,701
- Ironwood Physicians PC $24,405
- The Iowa Clinic PC $200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.